Results 141 to 150 of about 1,420 (176)

Nepenthes pitcher fluid for the green synthesis of silver nanoparticles with biofilm inhibition, anticancer and antioxidant properties. [PDF]

Sci Rep
Sabira O, Ajaykumar AP, Varma SR, Jayaraj KN, Kotakonda M, Kumar P, Vaikkathillam P, Sivadasan Binitha V, Alen AP, Raghu AV, Zeena KV.   +10 more
europepmc   +1 more source

Cost Trends of New-To-Market Neurologic Medications: An Insurance Claims Database Analysis. [PDF]

Neurology
Gusovsky Chevalier AV, Lin CC, Kerber K, Reynolds EL, Callaghan BC, Burke JF.   +5 more
europepmc   +1 more source

Multimodal Management of Supine Hypertension With Orthostatic Hypotension in an Elderly Male Patient With Parkinson's Disease. [PDF]

Cureus
Dayal M, Shah MS, Radfar N, Patel S, Thomas R.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Droxidopa in the Management of Hepatorenal Syndrome

Journal of Pharmacy Practice, 2022
Purpose Hepatorenal syndrome (HRS) is renal dysfunction associated with the hemodynamic consequences of advanced liver disease and cirrhosis. HRS is associated with a high mortality, and there remain high failure rates with first-line therapy aimed at improving perfusion. We report the use of droxidopa, an oral norepinephrine precursor, to aid in the
Andrea Bejjani, Youqi Zhang, Allison Behrens, Brian Murray, Neil Shah   +4 more
openaire   +2 more sources

Droxidopa for orthostatic hypotension

Journal of Hypertension, 2016
The systematic review and meta-analysis aims to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension, following its recent approvals in the United States.MEDLINE, EMBASE, PubMed, Cochrane Controlled Trials Register, Web of Science, ProQuest, and the WHO Clinical Trials Registry were searched.
Victoria, Strassheim, Julia L, Newton, Maw Pin, Tan, James, Frith   +3 more
openaire   +2 more sources

Droxidopa for Symptomatic Neurogenic Hypotension

Cardiology in Review, 2017
Droxidopa is a first-in-class, orally available, synthetic amino acid precursor of norepinephrine that received accelerated Food and Drug Administration approval in February 2014 after Orphan Drug status for a debilitating condition known as symptomatic neurogenic orthostatic hypotension.
openaire   +2 more sources

Droxidopa for neurogenic orthostatic hypotension

Expert Opinion on Orphan Drugs, 2015
Introduction: Neurogenic orthostatic hypotension is a disabling manifestation of autonomic failure seen in disorders such as multiple system atrophy, pure autonomic failure, Lewy body disease, Parkinson’s disease, autonomic neuropathies and dopamine β-hydroxylase deficiency.Areas covered: Droxidopa is an orally administered norepinephrine prodrug that ...
openaire   +1 more source

Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome

American Journal of Therapeutics, 2017
Background: Postural orthostatic tachycardia syndrome (POTS) is a constellation of signs and symptoms that occur when a patient is upright and relieved by recumbence. Currently, no drugs are labeled for the treatment for POTS.
Mohammed, Ruzieh, Osama, Dasa, Ann, Pacenta, Beverly, Karabin, Blair, Grubb   +4 more
openaire   +2 more sources